Vericel Co. (NASDAQ:VCEL) Shares Sold by Legato Capital Management LLC

Legato Capital Management LLC lessened its stake in shares of Vericel Co. (NASDAQ:VCEL - Free Report) by 58.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,720 shares of the biotechnology company's stock after selling 8,144 shares during the period. Legato Capital Management LLC's holdings in Vericel were worth $314,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of VCEL. International Assets Investment Management LLC raised its holdings in Vericel by 4,126.7% during the 3rd quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock valued at $27,000 after buying an additional 619 shares during the period. Farther Finance Advisors LLC increased its stake in Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock worth $77,000 after purchasing an additional 322 shares during the period. Meeder Asset Management Inc. purchased a new stake in Vericel in the third quarter worth $92,000. Finally, Geneos Wealth Management Inc. increased its stake in Vericel by 826.6% in the fourth quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock worth $138,000 after purchasing an additional 2,240 shares during the period.

Vericel Trading Up 1.3 %

Shares of VCEL traded up $0.72 during midday trading on Tuesday, reaching $57.81. 97,170 shares of the stock were exchanged, compared to its average volume of 388,032. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $63.00. The company's 50 day moving average is $57.82 and its two-hundred day moving average is $51.41. The company has a market capitalization of $2.85 billion, a P/E ratio of 963.66 and a beta of 1.72.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Vericel in a research note on Wednesday, January 15th. Canaccord Genuity Group increased their target price on Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. StockNews.com upgraded Vericel from a "sell" rating to a "hold" rating in a research note on Tuesday, December 24th. BTIG Research increased their target price on Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Finally, Truist Financial increased their price target on Vericel from $61.00 to $67.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Vericel presently has an average rating of "Moderate Buy" and a consensus price target of $63.14.

Insider Activity at Vericel

In related news, insider Jonathan Siegal sold 1,092 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $61.99, for a total transaction of $67,693.08. Following the sale, the insider now owns 1,206 shares of the company's stock, valued at $74,759.94. This trade represents a 47.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jonathan Mark Hopper sold 10,000 shares of the firm's stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $58.72, for a total value of $587,200.00. Following the sale, the insider now directly owns 58,371 shares in the company, valued at approximately $3,427,545.12. The trade was a 14.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,600 shares of company stock valued at $1,356,072 over the last quarter. 5.20% of the stock is owned by corporate insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.